TrialThe Lancet. Neurology2012

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.

Peter Connick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.